Top Hematology Research Papers

Overall: This large randomized head-to-head trial found a clinically meaningful reduction in bleeding with apixaban using an intervention that is immediately applicable to outpatient VTE treatment, although recurrent thrombotic outcomes were not presented.

Overall: A large randomized phase 3 trial found substantial progression-free and overall-survival advantages for talquetamab combinations, balanced against frequent serious toxicity and the practical burden of specialty-administered multidrug therapy.

Overall: A strong randomized trial shows meaningful survival and organ-outcome benefits, but treatment burden and the regimen's preexisting standard-of-care status temper its practical novelty.

Overall: A large, well-conducted randomized trial supports substantially longer cold storage without reduced hemostatic efficacy, although no patient-level superiority was shown and increased reexploration requires attention.

Overall: This long-term prospective study provides clinically important and highly relevant outcome data, but its practice impact is limited by the nonrandomized overall strategy and imprecision in the randomized radiotherapy comparison.

Overall: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis provides large, clinically relevant evidence against routine prophylaxis, but retrospective confounding and incomplete reporting of comparative estimates and harms temper confidence.

Overall: This large, directly applicable US cohort supports apixaban as having the most favorable comparative benefit-harm profile in younger adults with atrial fibrillation, but residual confounding and absent absolute event rates temper confidence.

Overall: A rigorous randomized trial found that YEARS safely avoided CTPA in 22% of patients with active cancer and suspected pulmonary embolism, but its acute hospital setting limits direct relevance to routine US primary care.

Overall: A large real-world registry supports clinically important benefits and a tradeoff with more non-major bleeding, but residual confounding, missing absolute effects, and confirmation of established practice limit its impact.

Overall: A rigorous, adequately sized trial supports a simpler aspirin-only strategy after arthroplasty, but the decision lies mainly outside routine US primary care and showed little difference in clinical outcomes.